IPO news, reviews, and company spotlights.

newcleo Moves Its $2.4 Billion Nuclear Deal Toward a Nasdaq Vote

newcleo’s $2.4 billion Nasdaq deal reaches its market test

Biotech IPOs Took the Week, Led by Braveheart and Latigo

Braveheart and Latigo lead a $1.17 billion biotech IPO week

Biotech issuers controlled the U.S. IPO tape in the week ended August 9, and the strongest deals did more than get through. Braveheart Bio priced above its range, Latigo Biotherapeutics landed at the top, Attovia...

Braveheart Bio Tests a $1.35 Billion Valuation With Fidelity in the Book

Braveheart tests $1.35B valuation with Fidelity interest

Jersey Mike's $1 Billion IPO Meets a Skeptical First Trade

JMKE's $1 billion IPO meets a skeptical first trade

Londian Wason Brings an $87 Million Demand Signal to NYSE

FOIL’s indicated orders exceed the base IPO

Jersey Mike’s Clears $1 Billion, but Buyers Set the Terms

Jersey Mike’s clears $1 billion as IPO buyers hold the line

Jersey Mike’s gave the week its scale and its clearest read on risk appetite. The sandwich franchisor and its shareholders sold 43.48 million shares at $23, the midpoint of the marketed range, for a $1 billion offering....

WISeKey's Nasdaq Reset Puts Voting Control in Focus

WISeKey's WQEY listing puts voting control in focus

Attovia Seeks $200 Million to Carry an Early Itch Signal Into Phase 2

Attovia asks IPO investors to fund an early itch signal

Game Your Game Reaches Nasdaq With No New Cash and a Streeterville Backstop

GYGY heads for Nasdaq as a no-proceeds direct listing, with Streeterville waiting behind it

Scribe Trades, Jersey Mike's Tests Size, Small IPOs Keep Cutting Terms

One IPO priced, two big launches hit the tape, and the small-cap calendar still looks fragile

The week of July 20 to July 26 finally produced one clean handoff from paperwork to public trading, but the broader calendar still looked selective. Scribe Therapeutics priced an upsized IPO at $15 a share for 8.58...

Csquare's IPO Cleared at Scale, but the Price Break Tells the Story

Csquare raised $1.05 billion at $21, below range, to pay down debt while Brookfield kept control

Scribe Therapeutics Brings Partner Backing to a High-Risk CRISPR IPO

Scribe tests biotech IPO demand with Lilly interest, Sanofi cash and a narrow data runway

Jersey Mike's Brings Scale to Market, but the IPO Still Looks Like Debt Cleanup

Jersey Mike's offers rare restaurant IPO scale, with sponsor control and leverage still central

IPO Week Review: Csquare and Standard Nuclear Reset Terms

Csquare cleared, Standard Nuclear cut hard, and the rest of the calendar split between direct listings and biotech filings

The week of July 13 to July 19 finally produced two real cash-raising tests for the U.S. IPO market. Csquare launched (https://www.csquare.com/blog/csquare-inc.-announces-launch-of-initial-public-offering) at 50 million...

Standard Nuclear Resets Its IPO to $150 Million, but the Fuel Scarcity Pitch Still Has a Real Audience

Standard Nuclear cuts its IPO ask, keeps the strategic fuel story intact

SK hynix gave the week its only clean IPO signal

Weekly IPO Review: SK hynix priced, the rest of the calendar amended

The week of July 6 through July 12 was easy to describe and harder to read through. SK hynix priced 177.9 million ADSs at $149 and raised about $26.5 billion (SEC final prospectus:...

SK hynix Prices a $26.5 Billion Nasdaq Deal Around AI Memory Demand

SK hynix brings cornerstone demand and a giant bank group to a $26.5 billion Nasdaq launch

Air Water Ventures Nears Vote With $96 Million PIPE and a Heavy Share Overhang

Air Water pushes toward market with a bigger PIPE, lower price, and a large prospective overhang

Columbia Financial's Conversion Deal Is Really a Merger Financing Test

Columbia's second-step conversion leaves a $281 million to $769 million bank book for Wall Street to clear

Rivian’s 75 Million-Share Sale Is a Georgia Financing Test, Not an IPO Sequel

Rivian taps the market for a 75 million-share raise tied to its DOE-backed Georgia buildout

Healthcare Took the Quarter; Tech Took the Dollars

Healthcare led Q2 IPO performance while tech dominated proceeds

Q2's clearest shift was that healthcare stopped being just a filing story and started leading the tape. In the quarter's 44 traded IPOs, healthcare and biotech produced 12 deals with average 17.4% first-day and 13.8%...

Bending Spoons Led a Selective IPO Week

Selective buyers backed Bending Spoons, Lime, ITG and Sinda while the lower end stayed stuck

The week did not reopen the IPO market in any broad sense. It showed that buyers will still fund size, recognizable sponsors, and straightforward use-of-proceeds stories, but they are not extending that benefit far down...

IQM Reaches Nasdaq, but the Real Story Is the PIPE

IQM's Nasdaq debut turns on PIPE cash, not a classic IPO book

Bending Spoons Priced Above Range, but the Real Bet Is the Next Deal

Bending Spoons’ IPO funded the acquisition machine, not just the portfolio

SeeQC’s Nasdaq Run Is Really a Financing Test

SeeQC still needs a $75 million IPO to close its quantum-SPAC merger

DPC Clears, Lime Looms, and the IPO Calendar Still Has to Earn It

DPC priced and traded; Lime, ITG, and CopperTech still need to clear

DPC was the week’s only clean handoff from filing work to public trading. Doncasters launched at $28 to $32, then priced an upsized 27,858,585-share IPO at $33 and raised about $919.3 million before expenses. The same...

Doncasters’ DPC Debut Shows the IPO Window Still Pays for Aerospace Scarcity

DPC priced above range, upsized the deal, and still traded like a shortage asset

Sinda’s IPO Has the Buyers Most Exploration Deals Only Promise

Sinda brings Fresnillo, Franco-Nevada and a real bank group to a pre-revenue silver float

CopperTech's IPO Is Really a Mine-Financing Test for Vedanta

CopperTech asks IPO buyers to fund only part of Vedanta's Zambia rebuild

Lime's IPO Finally Has Terms, but the Debt Clock Is the Real Story

Lime brings real scale to market, but this IPO still has to fix the balance sheet

Kardigan Led, First Carolina Cleared, and the Rest of the Calendar Stayed on Paper

Two deals reached real trading, but most of the IPO calendar still has more filing motion than market proof

Kardigan gave the week its only unambiguous risk-on signal. The biotech priced an upsized 25 million-share IPO at $16 for $400 million...

DSC’s $51 Million IPO Hinges on a $30 Million Named Order

DSC’s small Nasdaq IPO has one order big enough to define the book

Freenome Reaches Market With a Real PIPE and a Very Thin Public Float

Freenome’s $240 million PIPE gives FRNM real backing, but the float still looks fragile

SpaceX's $85.7 Billion IPO Close Turns the Calendar Into a Stress Test

SpaceX closed the largest IPO on the board, but public investors are really underwriting a combined launch, Starlink and AI capital stack

Sunshine Silver Cleared the IPO Market, but It Still Has to Build the Mine

Sunshine Silver priced at the bottom, filled the shoe, and brought a U.S. silver-antimony restart story to market

ReserveOne’s Nasdaq Pitch Is Really a Private-Capital Test

ReserveOne reaches effectiveness with $750 million of crypto-backed commitments behind RONE

Einride Reaches Nasdaq With Real Freight-Tech Traction and a Complicated Capital Stack

Einride’s public debut brings a live freight platform, a $113 million PIPE, and heavy structural baggage

Parabilis Turned a Biotech IPO Into a Platform Financing Event

Parabilis priced above range, brought Regeneron with it, and made the market fund the platform

BSTR Brings Bitcoin Treasury Scale, and Heavy SPAC Math, to Market

BSTR heads to a June vote with 30,021 BTC promised and public holders facing a thin slice

Weekly IPO Review: AVAT Led a Selective Week While the Bigger Calendar Mostly Tested Distribution

AVAT pushed ahead, INNIO launched, and most of late May’s heft still leaned secondary

The week of May 25 to May 31 did not broaden the IPO market so much as clarify its split. The cleanest progression came from special situations, not from a fresh run of conventional operating-company debuts. Avalanche...

Lincoln Clears, the Rest of the Calendar Stays in Filing Mode

Lincoln broke through; the rest of the IPO week stayed in amendment mode

Lincoln International priced its IPO on May 19 (https://www.prnewswire.com/news-releases/lincoln-international-announces-pricing-of-initial-public-offering-302776889.html), and by the next day’s NYSE debut...

Weekly IPO Review: Cerebras and Fervo reopened the window, but selectivity stayed brutal

Cerebras and Fervo reopened the IPO window. The rest of the calendar still had to fight for it.

Cerebras and Fervo did not just price in the week of May 11 through May 17. They reset the ceiling for what the 2026 IPO market will fund. Cerebras used a May 11 S-1/A to lift its range to $150 to $160 and expand the...

Selective Reopening: HawkEye and Odyssey Cleared, but Structure Still Did the Work

Weekly IPO Review: selective reopening, with HawkEye and Odyssey leading

Selective reopening, not a broad one The week looked better than it felt. HawkEye 360 jumped 30% in its NYSE debut after pricing 16 million shares at $26, the top of its range...

Biotech Took the Week. The Rest of the IPO Calendar Still Had Work to Do.

Biotech finally converted the pipeline into cash

The week of April 27 to May 3 finally turned IPO optimism into executed biotech paper. After X-Energy filed its final prospectus for a $1.02 billion IPO...

Weekly IPO Review: X-Energy Prices, Pershing Tests the Tape

X-Energy priced and popped. Pershing still set the week's agenda.

X-Energy broke the week open by doing the one thing most of the calendar still has not done: price cleanly and trade well. The company priced 44,254,659 shares at $23, above the $16 to $19 range in its April 20 S-1/A,...

IPO Week: The Large-Cap Window Reopened, Selectively

IPO week: Madison Air, Arxis and Kailera reopen the size window

The week of April 13 gave the IPO market a real size test. Madison Air, Arxis, Kailera, AEVEX and Alamar all crossed from filing work into priced offerings, raising roughly $4.5 billion before overallotments. That is...

HMH Carries a Thin IPO Week Across the Line

HMH prices; Elmet and Churchill refill the IPO queue

HMH was the week’s only real handoff from filing work to public trading. The offshore drilling equipment supplier priced 10.52 million Class A shares at $20, inside its $19 to $22 range, raised $210.4 million in gross...